Recommendations on how to monitor the patient with systemic lupus erythematosus in the clinic or at the bedside Chapter uri icon


MeSH Major

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Arthritis, Rheumatoid
  • Protein Kinase Inhibitors
  • Tumor Necrosis Factor-alpha


  • © 2012 Springer Science+Business Media New York. All rights are reserved.Systemic lupus erythematosus (SLE) is a heterogeneous disease with each patient having a unique expression of his or her disease. Clinicians will follow patients with SLE in the clinic when the disease is mild to moderate and or well controlled. At times patients with SLE are hospitalized and are monitored much more intensively according to extent of their disease activity. In clinical studies investigators frequently use complex outcome measures to determine disease activity although these are not yet routinely used in all clinics or at the bedside. Patients with SLE need to be assessed regularly for clinical symptoms, physical findings, and laboratory parameters to determine the extent of disease activity, damage from the disease, quality of life, comorbidities, and drug toxicity. Immunosuppressive therapy is frequently used to control the manifestations of SLE, and potential adverse effects of the medications must be monitored for on a regular basis during regular clinical evaluations and laboratory parameters should be performed when monitoring the patient with SLE.

publication date

  • September 2012



  • Book Chapter


Digital Object Identifier (DOI)

  • 10.1007/978-1-4614-1189-5_4

Additional Document Info

start page

  • 41

end page

  • 52


  • 9781461411895